AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call
NORTH CHICAGO, Ill., Jan. 5, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter 2022 financial results on Thursday,…
170,370$
-0,67%
Echtzeit-Aktienkurs Abbvie Inc.
Bid:
Ask:
Nachrichten zur Abbvie Inc. Aktie
AbbVie (ABBV) Gains As Market Dips: What You Should Know
In the latest trading session, AbbVie (ABBV) closed at $162.38, marking a +0.48% move from the previous day....…
ADC Therapeutics appoints AbbVie executive Mohamed Zaki as chief medical officer
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Cashing out in biotech in 2022: On-target predictions for AbbVie, Vertex and Genmab
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Samsung Bioepis speeding up US launch of Humira biosimilar
Samsung Bioepis has brought forward its interchangeability study of Hadlima to speed up its launch in the US market, according…
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could…
The Zacks Analyst Blog Highlights AbbVie, PepsiCo, Oracle, HSBC Holdings and The Progressive
AbbVie, PepsiCo, Oracle, HSBC Holdings and The Progressive are part of the Zacks top Analyst Blog....…
AbbVie (ABBV) Stock Moves -0.07%: What You Should Know
AbbVie (ABBV) closed the most recent trading day at $162.99, moving -0.07% from the previous trading session....…
Top Analyst Reports for AbbVie, PepsiCo & Oracle
Todays Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), PepsiCo, Inc. (PEP) and Oracle…
$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
read more...…
If You Invested $25,000 in AbbVie In 2020, This Is How Much You Would Have Today
In May 2020, the company closed on its acquisition of Botox maker Allergan....…
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
AbbVie (ABBV) closed the most recent trading day at $160.58, moving -0.56% from the previous trading session....…
Herpes treatment market to grow by 4.05% Y-O-Y in 2023; Increasing prevalence of herpes infection will drive growth - Technavio
NEW YORK, Dec. 19, 2022 /PRNewswire/ -- Herpes treatment market insights - Vendors: 15+, including AbbVie Inc., AiCuris Anti infective…
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could…
AbbVie (ABBV) Vraylar Gets FDA Nod for Major Depressive Disorder
FDA approves AbbVies (ABBV) Vraylar (cariprazine) for its fourth indication - the adjunctive treatment of patients with MDD....…
Time to Buy Eli Lilly (LLY) and AbbVie (ABBV) Stock for 2023?
AbbVies valuation, in particular, makes it a potentially strong candidate for 2023, while Eli Lillys growth could support its stock…
AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie
AbCellera (ABCL) inks a strategic collaboration with AbbVie to develop new antibody therapies across multiple indications. ABCL shares rise....…
AbbVie submits sNDA for Linzess for constipation in children
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie Submits SNDA For Linaclotide For Treatment Of Children, Adolescents
WASHINGTON (dpa-AFX) - AbbVie (ABBV) has submitted a supplemental New Drug Application for linaclotide or LINZESS to the FDA for…
AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age
If approved, linaclotide would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years…
Why Pfizer Stock Is Riskier Than AbbVie
Pfizer has a lot more revenue at risk over the next several years than AbbVie does....…
AbbVie to leave top pharma industry group
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AbbVie to leave leading U.S. drug industry trade group
...(Reuters) - AbbVie Inc is leaving Pharmaceutical Research... confirmed Reuters about the exits in the Politico…
AbbVie (ABBV) Gains As Market Dips: What You Should Know
AbbVie (ABBV) closed the most recent trading day at $164.86, moving +0.04% from the previous trading session....…
Insiderhandel: EVP, CHIEF HR OFFICER verkauft Aktien von AbbVie im Wert von 6.925.018$
Richmond, Timothy J. - Vorstand - Tag der Transaktion: 2022-12-12...…
Exicure says development collaborations with AbbVie, Ipsen terminated
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Sosei Heptares Receives $10 Million Milestone Payment in Discovery Collaboration with AbbVie Targeting Inflammatory Diseases
TOKYO and CAMBRIDGE, United Kingdom, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565),…
AbbVie Named to Dow Jones Sustainability World Index for 10th Straight Year
AbbVie Ranked #1 in Biotech Sector on the 2022 S&P Corporate Sustainability Assessment NORTH CHICAGO, Ill., Dec. 12, 2022 /PRNewswire/…
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas
Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) follicular lymphoma, previously…
AbbVie Presents Data For Navitoclax Combination For JAK Inhibitor-Naïve Myelofibrosis Patients
WASHINGTON (dpa-AFX) - AbbVie (ABBV) said the exploratory analysis from Cohort 3 of the Phase 2 REFINE study of investigational…
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients
Exploratory analysis from Cohort 3 of the Phase 2 REFINE study presented in an oral session at ASH NORTH CHICAGO,…
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Adds to Robust IMBRUVICA® (ibrutinib) Science
Updated data presented at ASH include CAPTIVATE and GLOW studies and real-world evidence abstracts NORTH CHICAGO, Ill., Dec. 10, 2022…
AbbVie (ABBV) Gains But Lags Market: What You Should Know
AbbVie (ABBV) closed at $165.99 in the latest trading session, marking a +0.36% move from the prior day....…
UPDATE 1-Unsubstantiated price hikes drove U.S. drug spending up $805 mln in 2021-report
... (Reuters) - Price increases spread among seven of
the 10 drugs in 2021 behind... Medical Officer David
Rind told Reuters.
In 2020,…
Is AbbVie Stock a Buy Now?
The pharmaceutical company prepared well as Humira approaches its patent cliff next year....…
AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress
-- Fifteen abstracts underscore AbbVies commitment to people living with migraine -- AbbVie to present late-breaking data from the Chronic…
Antiviral Drugs Global Market Report 2022: Featuring Key Players AbbVie, GlaxoSmithKline, Merck, Pfizer & More
DUBLIN, Dec. 5, 2022 /PRNewswire/ -- The "Antiviral Drugs Market by Mechanism of Action, Target Indication, Type of Drug Target,…
Übernahme von Botox-Hersteller gibt AbbVie Schub
Frankfurt (Reuters) - Der US-Pharmakonzern AbbVie profitiert von einer hohen Nachfrage nach seinem Blockbuster-Medikament Humira und der Übernahme des Botox-Herstellers…
Agentur - Boehringer und AbbVie in Gesprächen über Krebs-Allianz
Bangalore (Reuters) - Deutschlands zweitgrößter Pharmakonzern Boehringer Ingelheim steht einem Agenturbericht zufolge vor einer umfassenden Partnerschaft bei Krebs-Therapien mit dem…